Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation
Open Access
- 30 September 2024
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-17
Abstract
Background Immunotherapy faces a major challenge in treatment resistance, highlighting the need for efficacy biomarkers identification. The tumor microenvironment (TME) significantly influences treatment outcomes, necessitating molecular TME exploration to address immunotherapy resistance. Methods The study initially pinpointed IL7R as a pivotal TME gene and then examined its impact on TME’s CD8 + T cells at the single-cell level. Bulk-RNA analysis investigated IL7R function, immune cell infiltration related to IL7R in TCGA pan-cancer samples with its expression verified in clinical samples through immunohistochemistry. Genome instability and immune-related molecular expression associated with IL7R were also assessed. Furthermore, the clinical efficacy of IL7R was evaluated in various immunotherapy treatment cohorts. Results Our single-cell analyses and cell-cased experiment revealed that T cells with high IL7R expression tended to be non-terminal and correlated with favorable immunotherapy responses. High IL7R expression corresponded to increased immune and stromal cell signiture, immune pathway enrichment, and an immune-inflamed environment in Bulk-RNA analysis and immunohistochemistry verification. These patients exhibited higher proportions of memory T cells and M1 cells within the TME, along with frequent genome instability and immune molecular upregulation. While IL7R had varied prognostic impact across the TCGA dataset, patients with high IL7R expression showed extended survival under immunotherapy. Conclusion IL7R plays a critical role in shaping TME diversity across cancer types and holds promise as a relevant biomarker for predicting immunotherapy benefits.Keywords
Funding Information
- Medical and Health Technology Plan of Zhejiang Province (2022KY978, 2022KY980)
- Hangzhou Science and Technology Plan Project (202004A19)
This publication has 49 references indexed in Scilit:
- IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemiaBlood, 2019
- Prognostic genes of melanoma identified by weighted gene co‑expression network analysis and drug repositioning using a network‑based methodOncology Letters, 2019
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapiesNature Reviews Drug Discovery, 2019
- PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer PatientsCancer Cell, 2018
- Global characterization of T cells in non-small-cell lung cancer by single-cell sequencingNature Medicine, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Neoadjuvant PD-1 Blockade in Resectable Lung CancerNew England Journal of Medicine, 2018
- IL-7/IL-7 receptor axis stimulates prostate cancer cell invasion and migration via AKT/NF-κB pathwayInternational Immunopharmacology, 2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010